Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Nov 08 04:00PM ET
4.42
Dollar change
+0.48
Percentage change
12.18
%
IndexRUT P/E- EPS (ttm)-1.26 Insider Own21.23% Shs Outstand59.42M Perf Week17.55%
Market Cap294.65M Forward P/E- EPS next Y-1.20 Insider Trans0.00% Shs Float46.81M Perf Month40.10%
Income-59.20M PEG- EPS next Q-0.32 Inst Own52.93% Short Float10.49% Perf Quarter31.16%
Sales16.15M P/S18.24 EPS this Y45.31% Inst Trans25.71% Short Ratio10.23 Perf Half Y1.84%
Book/sh2.88 P/B1.53 EPS next Y-18.35% ROA-30.87% Short Interest4.91M Perf Year171.17%
Cash/sh2.36 P/C1.87 EPS next 5Y34.60% ROE-37.58% 52W Range1.35 - 6.85 Perf YTD145.56%
Dividend Est.- P/FCF- EPS past 5Y-118.72% ROI-31.27% 52W High-35.47% Beta1.30
Dividend TTM- Quick Ratio9.53 Sales past 5Y0.00% Gross Margin77.60% 52W Low227.41% ATR (14)0.25
Dividend Ex-Date- Current Ratio9.53 EPS Y/Y TTM55.81% Oper. Margin-425.85% RSI (14)69.80 Volatility6.64% 7.05%
Employees50 Debt/Eq0.12 Sales Y/Y TTM- Profit Margin-366.67% Recom1.00 Target Price10.00
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q30.95% Payout- Rel Volume1.93 Prev Close3.94
Sales Surprise- EPS Surprise14.28% Sales Q/Q- EarningsAug 14 AMC Avg Volume479.70K Price4.42
SMA2019.90% SMA5022.68% SMA2009.31% Trades Volume927,528 Change12.18%
Date Action Analyst Rating Change Price Target Change
Nov-08-24Initiated Stephens Overweight $13
Aug-08-24Initiated Stifel Buy $10
May-07-24Resumed Jefferies Buy $10
Feb-09-24Initiated BTIG Research Buy $8
Jan-23-24Initiated Leerink Partners Outperform $12
Sep-05-23Initiated RBC Capital Mkts Outperform $7
Nov-02-21Initiated Jefferies Buy $25
Nov-02-21Initiated Credit Suisse Outperform $19
Nov-02-21Initiated BofA Securities Neutral $16
Aug-29-24 07:30AM
Aug-14-24 04:05PM
Jul-29-24 08:00AM
Jun-28-24 04:30PM
Jun-10-24 07:30AM
07:30AM Loading…
May-30-24 07:30AM
May-14-24 03:53PM
08:40AM
07:30AM
May-09-24 07:30AM
Apr-12-24 09:55AM
Mar-28-24 04:30PM
Mar-27-24 07:30AM
Mar-26-24 12:00PM
Mar-21-24 01:53PM
09:11AM Loading…
09:11AM
07:30AM
Mar-13-24 08:00AM
Mar-07-24 04:30PM
Mar-05-24 04:45PM
Feb-27-24 08:00AM
Dec-29-23 04:30PM
Nov-28-23 07:00AM
Nov-07-23 04:30PM
Oct-23-23 11:27AM
Oct-13-23 09:00AM
Sep-27-23 09:18AM
Sep-14-23 05:03PM
Aug-31-23 04:01PM
Aug-23-23 08:35AM
07:00AM Loading…
Aug-11-23 07:00AM
Aug-01-23 04:01PM
Jun-30-23 05:00PM
May-30-23 08:30AM
May-24-23 06:45AM
May-11-23 07:00AM
Mar-31-23 05:00PM
Mar-30-23 02:16PM
Mar-22-23 06:45AM
Mar-16-23 07:30AM
Feb-13-23 08:00AM
Dec-23-22 04:45PM
Dec-01-22 06:45AM
Nov-01-22 06:30AM
Sep-30-22 05:00PM
Aug-15-22 07:00AM
Jul-12-22 06:45AM
Jun-28-22 06:35AM
Jun-21-22 10:40AM
May-19-22 06:35AM
May-13-22 08:03AM
May-07-22 10:34AM
Apr-27-22 06:35AM
Apr-13-22 06:35AM
Apr-08-22 01:05PM
Mar-29-22 11:00AM
06:35AM
Mar-22-22 06:35AM
Jan-10-22 11:17AM
Dec-15-21 08:00AM
Dec-09-21 08:30AM
Nov-15-21 07:15AM
Nov-10-21 08:00AM
Oct-08-21 03:31PM
Oct-07-21 10:24PM
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.